Erasca Stock Rockets 37% With 6-Day Winning Streak
Erasca (ERAS) – a developer of oral ERK1/2 inhibitors for RAS/MAPK cancers – hit a 6-day winning streak, with cumulative gains over this period amounting to 37%. The company’s market cap has surged by about $1.7 Bil over the last 6 days and currently stands at $6.4 Bil.
Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
But here is the interesting part. You are reading about this 37% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Qualys Stock: Strong Cash Flow Poised for a Re-Rating?
- Five-Year Tally: Dell Technologies Stock Delivers $22 Bil Gain
- Years of Rewards: $21 Bil From Lam Research Stock
- Intuit Stock Pulls Back to Support – Smart Entry?
- Could Cash Machine T-Mobile US Stock Be Your Next Buy?
- Pay Less, Gain More: MU Tops MACOM Technology Solutions Stock
The following table summarizes the return for ERAS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ERAS | S&P 500 |
|---|---|---|
| 1D | 3.2% | -0.6% |
| 6D (Current Streak) | 37.4% | 2.6% |
| 1M (21D) | 53.5% | 8.6% |
| 3M (63D) | 128.4% | 3.9% |
| YTD 2026 | 502.4% | 3.2% |
| 2025 | 48.2% | 16.4% |
| 2024 | 17.8% | 23.3% |
| 2023 | -50.6% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 75 S&P constituents with 3 days or more of consecutive gains and 43 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 28 | 32 |
| 4D | 24 | 4 |
| 5D | 15 | 4 |
| 6D | 1 | 3 |
| 7D or more | 7 | 0 |
| Total >=3 D | 75 | 43 |
Key Financials for Erasca (ERAS)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-157.1 Mil | $-131.4 Mil |
| Net Income | $-161.7 Mil | $-124.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-32.5 Mil | $-32.6 Mil |
| Net Income | $-30.6 Mil | $-29.1 Mil |
While ERAS stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.